Search - tctmd.com

Displaying 1 - 20 of 36

Sort: Relevancy | Date

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Conference News TCT 2016

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Michael O'Riordan

November 01, 2016

News Industry News

Sudy Indicates PCI Of NIRS-Defined Lipid-Rich Plaque Is Safe And Not Associated With A Greater Incidence Of Adverse Outcomes Compared To PCI of Non Lipid-Rich Plaque

November 01, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2016

Shelley Wood

September 30, 2016

News Daily News

TCTMD’s Top 10 Most Popular Stories for September 2016

Shelley Wood

September 30, 2016

News Daily News

Pharmacist Management of High Cholesterol Gets More Patients to Goal, Lowers LDL Levels: RxACT

Michael O'Riordan

September 29, 2016

News Daily News

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

Michael O'Riordan

September 20, 2016

News Conference News ESC 2016

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Michael O'Riordan

August 30, 2016

News Conference News ESC 2016

Long-term Exposure to Lower LDL Cholesterol, Blood Pressure Has Potential to Dramatically Cut CV Risk

Todd Neale

August 29, 2016

News Daily News

Noninvasive Testing Can Safely Spare a Large Proportion of Elderly Patients From Statin Therapy

Michael O'Riordan

August 23, 2016

News Daily News

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Michael O'Riordan

July 12, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

Statins Tied to Lower Mortality, Amputation Risks in PAD

Michael O'Riordan

May 09, 2016

News Conference News ACC 2016

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

Michael O'Riordan

April 02, 2016

News Daily News

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

Shelley Wood

February 16, 2016

News Daily News

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Michael O'Riordan

January 26, 2016

News Daily News

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Michael O'Riordan

December 15, 2015

News Conference News ESC 2015

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

Yael L. Maxwell

September 01, 2015

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

News Daily News

BARI 2D: El Mayor Control de los Factores de Riesgo en Pacientes con Diabetes Tipo 2 Mejora Supervivencia

Yael L. Maxwell

August 12, 2015

Advertisement

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Sudy Indicates PCI Of NIRS-Defined Lipid-Rich Plaque Is Safe And Not Associated With A Greater Incidence Of Adverse Outcomes Compared To PCI of Non Lipid-Rich Plaque

TCTMD’s Top 10 Most Popular Stories for September 2016

TCTMD’s Top 10 Most Popular Stories for September 2016

Pharmacist Management of High Cholesterol Gets More Patients to Goal, Lowers LDL Levels: RxACT

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Long-term Exposure to Lower LDL Cholesterol, Blood Pressure Has Potential to Dramatically Cut CV Risk

Noninvasive Testing Can Safely Spare a Large Proportion of Elderly Patients From Statin Therapy

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Statins Tied to Lower Mortality, Amputation Risks in PAD

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

BARI 2D: El Mayor Control de los Factores de Riesgo en Pacientes con Diabetes Tipo 2 Mejora Supervivencia

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content